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Abstract Cyclins, cyclin-dependent kinases, as well as
proteins cooperating with them are responsible for cell
cycle regulation which is crucial for normal development,
injury repair, and tumorigenesis. D-type cyclins regulate
G1 cell cycle progression by enhancing the activities of
cyclin-dependent kinases, and their expression is frequently
altered in tumors. Disturbances in cyclin expression were
also reported in melanocytic skin lesions. The objective of
the study was to evaluate the expression of cyclins D1 and
D3 in common, dysplastic, and malignant melanocytic skin
lesions. Forty-eight melanocytic skin lesions including
common nevi (10), dysplastic nevi (24), and melanomas
(14) were diagnosed by dermoscopy and excised. Expres-
sion of cyclin D1 and D3 was detected by immunohisto-
chemistry and quantiWed as percentage of immunostained
cell nuclei in each sample. In normal skin, expression of
cyclins D1 and D3 was not detected. The mean percentage
of cyclin D1-positive nuclei was 7.75% for melanoma
samples, 5% for dysplastic nevi samples, and 0.34% for
common nevi samples. For cyclin D3, the respective values
were 17.8, 6.4, and 1.8%. Statistically signiWcant diVer-
ences in cyclin D1 expression were observed between mel-
anomas and common nevi as well as between dysplastic
and common nevi (p = 0.0001), but not between melano-
mas and dysplastic nevi. Cyclin D3 expression revealed
signiWcant diVerences between all investigated lesion types
(p = 0.0000). The mean cyclin D1 and D3 scores of mela-
nomas with Breslow thickness <1 mm and >1 mm were not
signiWcantly diVerent. G1/S abnormalities are crucial for
the progression of malignant melanoma, and enhanced
cyclin D1 and D3 expression leading to increased melano-
cyte proliferation is observed in both melanoma and dys-
plastic nevi. In histopathologically ambiguous cases, lower
cyclin D3 expression in dysplastic nevi can be a diagnostic
marker for that lesion type.
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Introduction
The accuracy of the clinical diagnosis of melanocytic skin
lesion is limited. Conventional clinical diagnosis of mela-
noma based on ABCD criteria (A asymmetry, B irregular
borders, C various colors, D diameter >6 mm) is reliable
only in approximately 60% of cases and excludes small
melanomas (<6 mm). In addition, very early melanomas
may have a regular shape and homogeneous color [1, 3, 13,
14]. Dermoscopy (epiluminescence microscopy, surface
microscopy, and dermatoscopy) allows the identiWcation of
common and dysplastic nevi and also increases the diag-
nostic accuracy in cases of malignant melanomas [4, 7, 25,
26]. Its value in early and diVerential diagnosis of cutane-
ous melanoma has been clearly established by two indepen-
dent meta-analyses, and eYcient diagnostic algorithms
have been published [6, 15]. Although dermoscopy has
been introduced worldwide, it does not include evaluation
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546 Arch Dermatol Res (2010) 302:545–550of lesions at cellular level, which could enhance diagnostic
accuracy for melanocytic skin lesions [13].
The regulation of cell proliferation is crucial for normal
development, pathophysiological responses to injury, and
tumorigenesis. Progression through the cell cycle is con-
trolled by cyclins, cyclin-dependent kinases, and inhibitory
proteins. D-type cyclins (D1 and D3) are the Wrst cyclins to
be expressed in the G1 phase and bound to their kinases
CDK4 and CDK6. They play a major role in progression
through the G1 restriction point [10, 12, 20] by regulating
the function of pRb (retinoblastoma protein), which in its
hypophosphorylated form (the functionally active form)
can arrest cell cycle in G1 [12].
The role of cyclin D1 in the development, progression,
and prognosis of melanomas is controversial. Some authors
reported no diVerence in its expression in nevi and melano-
mas, whereas others showed overexpression of this protein
in melanomas [10, 20]. Cyclin D3 is an important regulator
of melanoma G1-S cycle progression. Its expression in mel-
anoma cells can be readily detected by immunohistochem-
istry and is associated with poor prognosis [22].
It was proved that cyclin D1 increases cell growth poten-
tial and has no inXuence on cell diVerentiation [19]. Recent
data suggest that cyclin D1 could be a marker of dysplastic
skin lesions as it was overexpressed within the dermal–
epidermal junction and/or papillary dermis in dysplastic
nevi [9]. Cyclin D3, on the other hand, has been shown to
have a dual function in proliferation and diVerentiation
[17], and cyclin D3-positive cells were present throughout
the lesion in most malignant melanomas, showing a close
association between its expression and proliferation in
superWcial spreading melanomas [10].
The clinical and histopathological features allow to discrim-
inate common nevi from melanomas; however, discrimination
between dysplastic nevi and melanomas can be sometimes
problematic, and the histologic criteria for diagnosis of the
former are still disputed [11]. Hence, in doubtful cases, an
additional diagnostic marker would be helpful. Studies of
cyclin expression compared melanocytic nevi and melanomas
[10, 12], but dysplastic nevi were not included in the analysis
as a separate group. Therefore, the aim of the present study
was to evaluate cyclin D1 and D3 expression in three groups of
melanocytic lesions: common nevi, dysplastic nevi, and malig-
nant melanomas and determine whether it could serve as a
diagnostic marker in histologically uncertain lesions.
Materials and methods
Dermoscopy
Forty-eight melanocytic skin lesions were collected from
patients at the Department of Dermatology, Jagiellonian
University Medical College, Krakow, Poland. The study
was approved by the Ethics Committee of the University in
May 2008. Written informed consent was obtained from
each patient following the guidelines of the Helsinki Decla-
ration. The lesions were diagnosed by dermoscopy using
Minolta Derlite photodermoscope. Surgical excision of
melanocytic skin lesions for histopathologic evaluation is
recommended when the lesion shows one of the following
clinical or dermoscopic features: (1) benign dermal papillo-
matous nevus located in highly traumatic area, (2) the pres-
ence of two out of three criteria of the 3-point checklist as a
screening method (1 asymmetry, 2 atypical network, and 3
blue-white structures) [25]), (3) the presence of one or two
melanoma-speciWc local criteria (atypical pigment network,
irregular streaks, irregular dots and globules, irregular
blotches, and blue-white structures). Lesions fulWlling the
above criteria were excised; in case of melanomas, the mar-
gin of normal skin (used as control samples) depended on
the thickness of melanoma: for melanoma in situ—5 mm;
for thickness <2 mm—1 cm; and for thickness >2 mm—2 cm.
The samples collected were common nevi (10), dysplastic
nevi (24), and melanomas (14), including nodular mela-
noma (7), superWcial spreading melanoma (3), and lentigo
maligna melanoma (4). Among the melanoma cases, six
samples were deWned as “thin”, with Breslow thickness
<1 mm, and eight samples as “thick” with Breslow thick-
ness >1 mm. None of the patients with melanoma had
metastases.
Histopathology and immunohistochemistry
The excised samples were Wxed in 10% buVered formalin
and embedded in paraYn. All lesions were evaluated using
the standard histopathologic criteria (hematoxylin and
eosin-stained sections) to reconWrm the diagnosis. The
histologic identiWcation of dysplastic nevi was based on the
presence of junctional nests of melanocytes often exhibit-
ing large pleomorphic nuclei and prominent nucleoli,
uniformly elongated rete ridges, and lymphocytic inWltra-
tions [11].
In three cases, dermoscopic diagnosis was altered after
histopathologic evaluation: two dermoscopically diagnosed
melanomas were identiWed as dysplastic nevi, and one
dermoscopically diagnosed superWcial spreading melanoma
was identiWed as lentigo maligna melanoma.
For immunohistochemistry, deparaYnized 6 m sec-
tions were subjected to antigen retrieval using 10 mM
citrate buVer, pH 6.0 (5 min preincubation followed by
9 min in microwave oven, 160 W, at 100°C, and 30 min
in vapor bath at 80°C). Next the sections were incubated
overnight at 4°C with primary mouse antibodies against
cyclin D1 or D3, followed by secondary goat anti-
mouse Cy3-conjugated antibody. The antibodies were123
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(Table 1). Cell nuclei were counterstained with DAPI
(Sigma, Saint Louis, MO, USA). Only nuclear immuno-
staining was scored as positive. In each sample, cyclin
expression was assessed as percentage of cyclin-positive
nuclei in the examined lesion. Microscopic examination,
digital imaging of sections, and image analysis were car-
ried out using Olympus BX-50 bright Weld/epiXuores-
cence microscope equipped with DP-71 camera
(Olympus, Japan) and PC-based image analysis software
(AnalySIS-FIVE®, Soft Imaging System GmbH, Münster,
Germany).
Statistical analysis
The relationship between expression of cyclins and the type
of melanocytic skin lesion (common nevi, dysplastic nevi,
melanoma) was evaluated by nonparametric ANOVA rank
Kruskal–Wallis test with p < 0.05 as condition for statisti-
cal signiWcance.
Results
In normal skin, the expression of cyclins D1 and D3 was
not detected. In melanocytic lesions, immunostaining was
observed in cell nuclei, with some cells also exhibiting very
weak cytoplasmic staining (Fig. 1). In common nevi, cyclin
D1 and D3 immunostaining was observed mainly in cells
located near the dermal–epidermal junction, whereas dys-
plastic nevi and melanomas exhibited a uniform distribu-
tion of cyclin-positive cells.
All investigated lesion samples showed expression of both
cyclins. The mean percentage of cyclin D1-positive nuclei in
melanomas, dysplastic nevi, and common nevi were 7.75, 5,
and 0.34%, respectively. The corresponding percentages for
cyclin D3 were 17.8, 6.4, and 1.08% (Table 2). Scoring data
are shown in Figs. 2 and 3. Statistically signiWcant diVerences
in cyclin D1 expression were observed between melanomas
and common nevi and between dysplastic and common nevi
(p = 0.0001), but not between dysplastic nevi and melanomas.
SigniWcant diVerences in cyclin D3 expression were observed
Table 1 Antibodies used in the 
study
Antibody against Supplier Code Dilution
Primary antibodies
Cyclin D1 Novocastra Laboratories Ltd., Newcastle, UK NCL-CYCLIN D1 1:20




Jackson IR, West Grove, PA, USA 115-165-146 1:400
Fig. 1 Micrographs showing 
cyclin D3 expression (dim red 
nuclear immunoXuorescence) in 
common nevus (a), dysplastic 
nevus (b), and melanoma (c). 
Note weak signals emitted by 
three nuclei in common nevus 
and gradually increasing number 
of immunopositive nuclei in 
dysplastic nevus and melanoma. 
DAPI counterstaining of cell 
nuclei, bright orange 
nonspeciWc Xuorescence of red 
blood cells. Original 
magniWcation £400123
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nevi, between melanomas and common nevi and between
dysplastic and common nevi (p = 0.0000; Table 2). The mean
cyclin D1 and D3 scores of melanomas with Breslow thick-
ness <1 mm were not signiWcantly diVerent from those of
melanomas with Breslow thickness >1 mm (Figs. 4, 5).
Discussion
In the present study, dermoscopy was employed to identify
melanocytic skin lesions: common nevi, dysplastic nevi, and
melanomas. We excised common nevi only if they were
located in a highly traumatic area; patients were worried
about their possible malignant transformation and insisted
on their removal. Since the dysplastic nevi can be an inter-
mediate step in tumor progression from common acquired
melanocytic nevi to melanomas [2, 21], we excised them in
cases when the dermoscopic appearance of the nevus did not
allow to exclude melanoma with certainty.
In the three types of melanocytic skin lesions, immuno-
histochemistry was used to evaluate the expression of cyc-
lins D1 and D3. These cyclins, belonging to G1 cyclin
family, are important for the passage of cells through the G1
phase into the S phase. We found the same expression pat-
tern for both cyclins: expression was the highest in melano-
mas, the lowest in the common nevi, and intermediate in the
dysplastic nevi, with all diVerences statistically signiWcant
Table 2 DiVerences in cyclin D1 and D3 expression in melanocytic
skin lesion
Cyclin D1: Kruskal–Wallis test: H (2, N = 48) = 18,77577,
* signiWcant, p = 0.0001
Cyclin D3: Kruskal–Wallis test: H (2, N = 48) = 20,32182,
* signiWcant, p = 0.0000
R mean percentage of immunostained cell nuclei







Dysplastic nevi 1.969736 2.995276*
Common nevi 4.322768* 2.995276*







Dysplastic nevi 2.739677* 2.478140*
Common nevi 4.478033* 2.478140*
Fig. 2 Cyclin D1 expression (percentage of immunostained cell
nuclei) in melanocytic lesions
Fig. 3 Cyclin D3 expression (percentage of immunostained cell
nuclei) in melanocytic lesions
Fig. 4 Cyclin D1 expression (percentage of immunostained cell
nuclei) in melanomas according to tumor thickness123
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cyclin D1. Coordinated expression of both cyclins in
dysplastic nevi and malignant tumors indicates that more than
one D-type cyclin may be involved in tumor development.
Although no cyclin D1 expression could be detected
in normal skin areas, we observed very few (0.34%) cyclin
D1-positive cell nuclei in common nevi, in contrast to data
reported by other authors who failed to Wnd cyclin D1
expression in any common nevi [10]. Cyclin D1-positive
cells were mostly located close to the dermal–epidermal
junction, which corresponds to the observations of Stefanaki
et al. [23] that common nevi shows either rare cyclin D1 pos-
itivity or a zonal expression pattern. This is quite distinct
from melanomas which display diVuse cyclin D1 expression.
Previous studies have demonstrated various abnormali-
ties in cyclin D1 and D3 expression in sporadic and familial
melanomas [10, 12, 20, 24]. Cyclin D1 was observed to be
recurrently overexpressed in melanomas, and its downregu-
lation had a signiWcant impact on melanoma cell growth
[23]. We found signiWcantly higher cyclin D1 expression in
melanomas compared with common nevi, suggesting that
cyclin D1 may play a role in the development of the malig-
nant phenotype. Some authors reported the same relation-
ship between common nevi and malignant melanocytic
tumors, but others found no signiWcant diVerences in the
expression of cyclin D1 between those two groups [12, 20].
Cyclin D3 expression is required for eYcient G1-S cell
cycle progression, proliferation, and diVerentiation of mela-
nocytes [5, 18, 22]. We found signiWcantly higher cyclin D3
expression in melanomas as compared with dysplastic nevi.
In case of cyclin D1, the diVerence also existed, but did not
reach the level of signiWcance. However, dysplastic nevi
revealed signiWcantly higher expression of both cyclins as
compared with common nevi. It corresponds to results
reported by Ewanowich et al. [9] who found overexpression
of cyclin D1, especially in the region of epidermal–dermal
junction. Enhanced cyclin expression in dysplastic nevi sup-
ports the view that cyclins are activated during the transition
from benign to malignant phenotype of melanocytic skin
lesion, and that dysplastic nevi represents an intermediate
stage in this process. Our Wndings also suggest that cyclin
D3 expression could be a marker for dysplastic melanocytic
lesions in histopathologically ambiguous lesions, being sig-
niWcantly lower than in melanomas.
No relationship between thickness of melanoma and cyclin
D1 and D3 expression observed in the present study seems to
be a controversial Wnding. In case of cyclin D1, it remains in
agreement with previous data reported in the literature [12, 20]
although, in a recent study, de Sa et al. [8] demonstrated higher
expression of cyclin D1 in thin superWcial spreading melano-
mas as compared to thick ones. In case of cyclin D3, the results
of other studies are discrepant: its expression was found to be
higher in thicker superWcial spreading melanomas, while the
opposite relation was observed in nodular melanomas [10].
Jørgensen et al. [16] reported an association between cyclin D3
expression, cell proliferation, and disease progression in super-
Wcial spreading melanomas, and also observed higher expres-
sion being signiWcantly associated with the thickness of
primary tumors. We could not Wnd any signiWcant association
between melanoma thickness and cyclin expression, possibly
because of relatively small number of melanoma samples.
In summary, the present study has conWrmed that G1/S
abnormalities are crucial in the progression of melanocytic
skin lesions, and that deregulation of cyclin D1 and D3
expression leading to increased melanocyte proliferation
points to candidate proteins involved in melanoma genesis
as possible therapeutic targets. Cyclin D3, showing signiW-
cantly lower expression in dysplastic nevi than in melano-
mas, but higher than in common nevi, seems to be a
suitable diagnostic marker for diVerentiation of these
lesions in histologically doubtful cases.
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